Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||PIK3CA mutant|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CDKN2A mut PIK3CA mut||breast cancer||sensitive||Sapanisertib||Preclinical||Actionable||In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).||25261369|
|PIK3CA mut PTEN loss||breast cancer||resistant||Alpelisib||Case Reports/Case Series||Actionable||In a clinical case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN, and the corrresponding patient-derived xenograft model demonstrated resistance to Alpelisib (BYL719)-induced inhibition of tumor growth (PMID: 25409150).||detail... 25409150|
|PIK3CA mut PTEN loss||breast cancer||sensitive||Buparlisib||Preclinical - Pdx||Actionable||In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).||detail...|
|PIK3CA mut PTEN loss||breast cancer||sensitive||Alpelisib + AZD6482||Preclinical - Pdx||Actionable||In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).||detail...|
|PIK3CA mut PTEN loss||prostate cancer||sensitive||PKI-179||Preclinical - Cell culture||Actionable||In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).||20797855|
|FGFR1 over exp PIK3CA mut||estrogen-receptor positive breast cancer||sensitive||Alpelisib + Lucitanib||Preclinical - Cell culture||Actionable||In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994).||27126994|
|BRAF V600E PIK3CA mut||colorectal cancer||sensitive||ASN003||Preclinical - Cell line xenograft||Actionable||In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).||detail...|